The significance of PAK2 might be explained by its involvement in multiple pathways with the potential to drive ECM remodelling and motility of cancer cells, including those featuring cytoskeletal effector proteins (Misra et al, 2005; Kumar et al, 2006; Chen et al, 2009; Flate & Stalvey, 2014; Radu et al, 2014). This evidence concerns the gene PAK2 and cancer.